表紙
市場調查報告書

Frost Radar:製藥產業的藥物研發人工智能

FROST RADAR: Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry, 2020

出版商 Frost & Sullivan 商品編碼 936676
出版日期 內容資訊 英文 60 Pages
商品交期: 最快1-2個工作天內
價格
Frost Radar:製藥產業的藥物研發人工智能 FROST RADAR: Artificial Intelligence for Drug Discovery in the Pharmaceutical Industry, 2020
出版日期: 2020年05月05日內容資訊: 英文 60 Pages
簡介

本報告提供製藥產業的藥物研發人工智能市場相關調查分析,提供利用Frost Radar調查方法的企業市場定位相關之系統性資訊。

目錄

策略性必要事項與成長環境

  • 策略性必要事項
  • 成長環境

FROST RADAR

C2A (主要企業)

  • ACURASTEM, INC.
  • AI THERAPEUTICS
  • ATOMWISE
  • BenevolentAI
  • BERG
  • BIOVISTA INC.
  • COTINGA PHARMACEUTICALS INC.
  • EVAXION BIOTECH
  • EXSCIENTIA LTD.
  • GRITSTONE ONCOLOGY, INC.
  • HEALX
  • INSILICO MEDICINE
  • LANTERN PHARMA, INC.
  • PHARNEXT
  • RECURSION PHARMACEUTICALS
  • twoXAR

策略性考察察

  • 策略性考察

主要的參與企業的影響

  • FROST Radar的重要性
  • FROST Radar支援CEO的成長團隊
  • FROST Radar支援投資者
  • FROST Radar支援客戶
  • FROST Radar強化董事會

Frost Radar分析

  • FROST Radar:基準化未來增長潛力
  • 免責聲明
目錄
Product Code: K409-52

Benchmarking Future Growth Potential

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16% in 2011 to almost 11% in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniques to address the understanding around targets and leads are inefficient. The increasing volume and veracity of clinical and research data compels traditional providers to leverage converging technologies such as artificial intelligence (AI), machine learning, natural language processing, and advanced analytics to shift from static to dynamic and adaptive data management practices. The ecosystem for supporting this growth has matured: several technology start-ups and large commercial vendors have already started delivering the impact through their products and solutions catering to drug discovery. While the benefits over the next 2 to 3 years are expected to be achieved through improved drug pipelines and faster clinical approval of new molecules, beyond that companies that integrate AI solutions will see significant impact on efficiency, cost savings and commercial success depending on their business goals.

Frost & Sullivan analysis shows that the AI impact over the pharma value chain can more than double what is achievable using traditional analytics and capture between 2% and 3% of the industry revenue, amounting to more than $50 billion in potential annual impact. This Frost Radar™ recognizes the participants that are at the forefront of developing and employing the tools. This is an industry-first benchmarking study that provides an introduction to the ecosystem and recognizes the pioneering companies.

The Frost Radar reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar methodology. The document presents competitive profiles on each of the companies in the Frost Radar based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in the industry and benchmarks them across 10 criteria on the Frost Radar, where the leading companies in the industry are then positioned. Industry leaders on both the Growth and Innovation indices are recognized as best practice recipients.

Table of Contents

Strategic Imperative and Growth Environment

  • Strategic Imperative
  • Strategic Imperative (continued)
  • AI for Drug Discovery Market Segmentation
  • Growth Environment
  • Growth Environment (continued)

FROST RADAR™

  • Frost Radar™
  • Frost Radar™
  • Frost Radar™
  • Frost Radar™

Companies to Action

  • ACURASTEM, INC.
  • ACURASTEM, INC. (continued)
  • AI THERAPEUTICS
  • AI THERAPEUTICS (continued)
  • ATOMWISE
  • ATOMWISE (continued)
  • BenevolentAI
  • BenevolentAI (continued)
  • BERG
  • BERG (continued)
  • BIOVISTA INC.
  • BIOVISTA INC. (continued)
  • COTINGA PHARMACEUTICALS INC.
  • COTINGA PHARMACEUTICALS INC. (continued)
  • EVAXION BIOTECH
  • EVAXION BIOTECH (continued)
  • EXSCIENTIA LTD.
  • EXSCIENTIA LTD. (continued)
  • GRITSTONE ONCOLOGY, INC.
  • GRITSTONE ONCOLOGY, INC. (continued)
  • HEALX
  • HEALX (continued)
  • INSILICO MEDICINE
  • INSILICO MEDICINE (continued)
  • LANTERN PHARMA, INC.
  • LANTERN PHARMA, INC. (continued)
  • PHARNEXT
  • PHARNEXT (continued)
  • RECURSION PHARMACEUTICALS
  • RECURSION PHARMACEUTICALS (continued)
  • twoXAR
  • twoXAR (continued)

Strategic Insights

  • Strategic Insights

NEXT STEPS: LEVERAGING THE FROST RADAR™ TO EMPOWER KEY STAKEHOLDERS

  • SIGNIFICANCE OF BEING ON THE FROST Radar™
  • FROST Radar™ EMPOWERS THE CEO'S GROWTH TEAM
  • FROST Radar™ EMPOWERS INVESTORS
  • FROST Radar™ EMPOWERS CUSTOMERS
  • FROST Radar™ EMPOWERS THE BOARD OF DIRECTORS

Frost Radar™Analytics

  • FROST Radar™: BENCHMARKING FUTURE GROWTH POTENTIAL
  • FROST Radar™: BENCHMARKING FUTURE GROWTH POTENTIAL
  • FROST Radar™: BENCHMARKING FUTURE GROWTH POTENTIAL
  • Legal Disclaimer